INSP — Inspire Medical Systems, Inc.

Inspire Medical Systems (INSP) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: Increased 12% to $269 million.
• Full Year Revenue: Increased 14% to $912 million, driven by growth at existing centers and new center additions.
• Net Income: Q4 net income per diluted share rose to $4.66, up $3.51 year-over-year; full year net income per diluted share increased to $4.89, up $3.09.
• Adjusted Net Income: Q4 adjusted net income per diluted share was $1.65, up $0.51; full year adjusted net income per diluted share was $2.42, up $0.80.
• Operating Cash Flow: Q4 operating cash flow was $52 million, totaling $117 million for the year.
• Share Repurchases: $50 million in Q4, totaling $175 million for the year.
• Cash Position: Ended Q4 with $405 million in cash and investments.

2. Strategic Updates and Business Highlights

• Reimbursement Challenges: The transition to CPT code 64582 with a -52 modifier for the Inspire V procedure may reduce professional fees by 10% to 50%, impacting physician willingness to perform the procedure.
• Inspire V System Performance: The Inspire V system showed superior outcomes compared to Inspire IV, with a 79.5% responder rate in the Singapore study.
• Market Expansion: Completed physician training and contracting for over 90% of centers for Inspire V.
• R&D Initiatives: Received FDA approval for 3 Tesla MRI compatibility and initiated development of Inspire VI, which will include sleep detection and auto-activation features.
• Patient Marketing: Increased social media activity and demand for Inspire therapy noted in Q4.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Revised to $950 million to $1 billion, reflecting potential impacts from coding uncertainty and reimbursement changes.
• Expected Growth: Anticipated revenue growth of 4% to 10% in 2026, with a flat revenue expectation for Q1 due to coding uncertainty.
• Adjusted Operating Margin: Expected to be between 6% to 8% for 2026.
• Net Income Guidance: Projected net income per diluted share between $1.23 and $1.81.

4. Challenges and Points of Concern

• Reimbursement Landscape: The shift to the -52 modifier could significantly impact physician reimbursement, leading to a potential decrease in procedures performed.
• WISeR Program Impact: The Medicare prior authorization program has caused initial disruptions in six states, affecting procedure approvals.
• Competitive Pressures: Increased competition from other therapies, such as GLP-1s, and the need to maintain market share against emerging products.
• Operational Adjustments: The company is strategically consolidating territories and hiring field clinical representatives to optimize operations amidst these challenges.

5. Notable Q&A Insights

• Clarity on Coding: Management emphasized the need for clarity on reimbursement and coding to minimize the impact of the -52 modifier.
• Physician Engagement: Majority of physicians are in private practice, with academic centers less affected by fee reductions, which could influence procedure volumes.
• Future Coding Strategy: The company is pursuing a new CPT code, with a long-term goal of establishing a stable reimbursement structure by 2028.
• Patient Flow Management: The company is focused on ensuring that patient referrals continue despite potential physician hesitance due to reimbursement issues.

In summary, while Inspire Medical Systems reported strong financial results for Q4 2025, the company faces significant challenges related to reimbursement changes that could impact future growth. Strategic initiatives are in place to address these challenges, but the evolving landscape presents risks that will require careful navigation in 2026 and beyond.